SynthesisBMC medicine2025
Does ambient PM
Synthesis in BMC medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Modelled Physical Activity Benefits and PMToxics · 2026Article
- Lung Cancer in Never-Smokers: Risk Factors, Driver Mutations, and Therapeutic Advances.Diagnostics (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
Abstract
backgroundThis study assessed whether higher levels of fine particulate matter (PM
methodsWe conducted two complementary investigations. First, a systematic review and meta-analysis (per PRISMA guidelines) identified eligible cohort studies from PubMed, Web of Science, Embase, and SPORTDiscus (from inception to 6 January 2025) that examined the independent or joint associations of LTPA and PM₂.₅ with mortality among adults (≥ 18 years). Second, an individual-level pooled analysis using harmonized data from three cohorts was performed using Cox regression modeling to assess the associations observed in the meta-analysis.
resultsIn Study One, a total of seven cohort studies (n = 1,515,094; deaths = 115,196) were included in the meta-analysis, revealing that the reduction in all-cause mortality risk diminished with higher PM
conclusionsLTPA is beneficial for all-cause, cardiovascular, and cancer mortality even at relatively high PM PROSPERO REGISTRATION NUMBER: CRD42023395364.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.